Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ariadna Tibau

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Plos One|June 10, 2022
Clinical benefit of cancer drugs approved in Switzerland 2010-2019Roman Adam, Ariadna Tibau, Consolación Molto Valiente, et al.
The Lancet. Oncology|May 4, 2020
Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysisKerstin N Vokinger, Thomas J Hwang, Thomas Grischott, et al.
Journal of the National Cancer Institute|July 21, 2025
Assessing Outcomes Emerging After Conversion to Regular Approval for Cancer Drug Indications Granted Accelerated Approval, 1992-2021Ariadna Tibau, Alejandra Romano, Ian T T Liu, et al.
Plos One|March 4, 2014
Extended adjuvant tamoxifen for early breast cancer: a meta-analysisMustafa Al-Mubarak, Ariadna Tibau, Arnoud J Templeton, et al.
Oncotarget|March 31, 2018
Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancerAriadna Tibau, Geòrgia Anguera, Fernando Andrés-Pretel, et al.
Cancers|April 26, 2025
The Effect of Staging Intervals on Progression-Free Survival in Registration Studies of Oncologic Drugs: A Meta-AnalysisJonas A Zuellig, Roman Adam, Filomena Udry, et al.
Human Pathology|April 19, 2011
Low-density lipoprotein receptor-related protein 1 is associated with proliferation and invasiveness in Her-2/neu and triple-negative breast carcinomasLluis Catasus, Alberto Gallardo, Vicenta Llorente-Cortes, et al.
Critical Reviews in Oncology/Hematology|July 27, 2024
The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic reviewAreen Abu Remilah, Bilal Krayim, Eitan Amir, et al.
Cancer|July 23, 2020
Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug AdministrationConsolación Molto, Thomas J Hwang, Maria Borrell, et al.
JAMA Oncology|July 1, 2021
Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and EuropeKerstin N Vokinger, Thomas J Hwang, Paola Daniore, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Plos One|June 10, 2022
Clinical benefit of cancer drugs approved in Switzerland 2010-2019Roman Adam, Ariadna Tibau, Consolación Molto Valiente, et al.
The Lancet. Oncology|May 4, 2020
Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysisKerstin N Vokinger, Thomas J Hwang, Thomas Grischott, et al.
Journal of the National Cancer Institute|July 21, 2025
Assessing Outcomes Emerging After Conversion to Regular Approval for Cancer Drug Indications Granted Accelerated Approval, 1992-2021Ariadna Tibau, Alejandra Romano, Ian T T Liu, et al.
Plos One|March 4, 2014
Extended adjuvant tamoxifen for early breast cancer: a meta-analysisMustafa Al-Mubarak, Ariadna Tibau, Arnoud J Templeton, et al.
Oncotarget|March 31, 2018
Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancerAriadna Tibau, Geòrgia Anguera, Fernando Andrés-Pretel, et al.
Cancers|April 26, 2025
The Effect of Staging Intervals on Progression-Free Survival in Registration Studies of Oncologic Drugs: A Meta-AnalysisJonas A Zuellig, Roman Adam, Filomena Udry, et al.
Human Pathology|April 19, 2011
Low-density lipoprotein receptor-related protein 1 is associated with proliferation and invasiveness in Her-2/neu and triple-negative breast carcinomasLluis Catasus, Alberto Gallardo, Vicenta Llorente-Cortes, et al.
Critical Reviews in Oncology/Hematology|July 27, 2024
The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic reviewAreen Abu Remilah, Bilal Krayim, Eitan Amir, et al.
Cancer|July 23, 2020
Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug AdministrationConsolación Molto, Thomas J Hwang, Maria Borrell, et al.
JAMA Oncology|July 1, 2021
Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and EuropeKerstin N Vokinger, Thomas J Hwang, Paola Daniore, et al.
Pageof 5